Otsuka America Pharmaceutical, Inc Sustainability Profile
Otsuka America Pharmaceutical, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1973, the company has established a strong presence in key operational regions, focusing on innovative treatments in areas such as mental health, nephrology, and oncology. Otsuka is renowned for its unique products, including the groundbreaking antipsychotic medication Abilify and the first oral treatment for polycystic kidney disease, Jynarque. These offerings highlight the company's commitment to addressing unmet medical needs through research and development. With a reputation for innovation and a robust pipeline, Otsuka America continues to solidify its market position, contributing significantly to advancements in healthcare.
DitchCarbon Score
How does Otsuka America Pharmaceutical, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka America Pharmaceutical, Inc's score of 60 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka America Pharmaceutical, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Otsuka Pharmaceutical Co., Ltd., which cascades its climate commitments and initiatives through its corporate family structure. While Otsuka America Pharmaceutical, Inc. does not report its own emissions, it inherits climate commitments from Otsuka Holdings Co., Ltd. at a cascade level of three. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across the organisation. However, specific reduction targets or achievements for Otsuka America Pharmaceutical, Inc. have not been disclosed. The company is also aligned with the RE100 initiative, which focuses on transitioning to 100% renewable electricity, although details on specific commitments or timelines are not provided. Overall, while Otsuka America Pharmaceutical, Inc. is part of a broader corporate strategy for climate action, specific emissions data and reduction targets remain unspecified at this level.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | - | - | - | 000,000,000 | - | - |
| Scope 2 | 159,000,000 | - | - | - | - | 0,000,000 | - | - |
| Scope 3 | 866,000,000 | - | - | - | 000,000,000 | - | - | - |
How Carbon Intensive is Otsuka America Pharmaceutical, Inc's Industry?
How Carbon Intensive is Otsuka America Pharmaceutical, Inc's Location?
Otsuka America Pharmaceutical, Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Otsuka America Pharmaceutical, Inc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
